Glycogen synthase kinase-3␤ (GSK3␤) is a central figure in Wnt signaling, in which its activity is controlled by regulatory binding proteins. Here we show that binding proteins outside the Wnt pathway also control the activity of GSK3␤. DNA damage induced by camptothecin, which activates the tumor suppressor p53, was found to activate GSK3␤. This activation occurred by a phosphorylation-independent mechanism involving direct binding of GSK3␤ to p53, which was confined to the nucleus where p53 is localized, and mutated p53 (R175H) bound but did not activate GSK3␤. Activation of GSK3 promoted responses to p53 including increases in p21 levels and caspase-3 activity. Thus, after DNA damage there is a direct interaction between p53 and GSK3␤, and these proteins act in concert to regulate cellular responses to DNA damage. C ells respond to DNA damage by activating signaling cascades that cause cell-cycle arrest to allow repair or cause apoptosis to eliminate irreparably damaged cells (1-3). After DNA damage, the tumor-suppressor protein p53 is a key intermediate in both cell-cycle arrest and apoptosis, and dysfunctional p53 is one of the most prevalent causes of tumor formation in humans (4-6). Apoptosis induced by p53 after DNA damage is executed by cysteine͞aspartate proteases such as the effector caspase-3, but regulatory mechanisms linking p53 to caspase activation remain unclear. Glycogen synthase kinase-3␤ (GSK3␤) is a key enzyme in several signaling pathways (7, 8) including the Wnt pathway, through which its activity is controlled by regulatory binding proteins, and is an important proapoptotic signaling enzyme (9-12). Furthermore, apoptotic stimuli induce nuclear accumulation of GSK3␤ (13), colocalizing it with p53. Therefore, we examined whether there is a functional interaction between p53 and GSK3␤ and whether p53-mediated caspase activation caused by DNA damage involves GSK3␤.
C ells respond to DNA damage by activating signaling cascades that cause cell-cycle arrest to allow repair or cause apoptosis to eliminate irreparably damaged cells (1) (2) (3) . After DNA damage, the tumor-suppressor protein p53 is a key intermediate in both cell-cycle arrest and apoptosis, and dysfunctional p53 is one of the most prevalent causes of tumor formation in humans (4) (5) (6) . Apoptosis induced by p53 after DNA damage is executed by cysteine͞aspartate proteases such as the effector caspase-3, but regulatory mechanisms linking p53 to caspase activation remain unclear. Glycogen synthase kinase-3␤ (GSK3␤) is a key enzyme in several signaling pathways (7, 8) including the Wnt pathway, through which its activity is controlled by regulatory binding proteins, and is an important proapoptotic signaling enzyme (9) (10) (11) (12) . Furthermore, apoptotic stimuli induce nuclear accumulation of GSK3␤ (13) , colocalizing it with p53. Therefore, we examined whether there is a functional interaction between p53 and GSK3␤ and whether p53-mediated caspase activation caused by DNA damage involves GSK3␤.
Methods
Cell Culture and Treatments. Human neuroblastoma SH-SY5Y and H1299 cells were grown as described (11, 14) . Cells were washed and incubated in serum-free medium for 2 h before experimental treatments, and previously described procedures were used for preparation of cell lysates (13) and for measurements of caspase-3 activity (11) . Full-length GSK3␤-binding protein (GBP) cDNA (provided by D. Kimelman) was amplified by PCR (primers 5Ј-AGT TAGTCGACGCCATGCCGTGTCG-CAAGGAG-3Ј and 5Ј-ACTATGCGGCCGCTTGCACGGTT-GTTCCAGT GCA-3Ј), digested with SalI and NotI, and inserted into the SalI͞NotI sites of the pCMV͞Myc͞nuc vector (Invitrogen) to make GBP with a nuclear localization signal and a Myc epitope. For construction of pcDNA3.1͞XG114, fulllength dominant negative GSK3␤ (provided by D. Kimelman) was excised from XG114 vector using BamHI and subcloned into the BamHI restriction site of pcDNA3.1(Ϫ) (Invitrogen). All constructs were verified by DNA sequencing. SH-SY5Y cell lines stably expressing nuclear localization signal-GBP or dominant negative GSK3␤ were generated as described (11) .
Immunoblot Analysis. Samples were mixed with Laemmli sample buffer (2% SDS) and placed in a boiling water bath for 5 min. Proteins were resolved in SDS-polyacrylamide gels and transferred to nitrocellulose, membranes were probed with antibodies to p53 (Upstate Biotechnology, Lake Placid, NY), poly(ADPribose) polymerase (PARP), p21 (BD PharMingen, San Diego), GSK3␤ (BD Transduction, San Diego), or phospho-Ser-9-GSK3␤ (New England Biolabs), and each experiment was carried out two or more times.
GSK3␤ Activity. The activity of GSK3␤ was measured essentially as described (13) . Briefly, GSK3␤ was immunoprecipitated from cell lysates (100 g of protein) or nuclear extracts (25 g of protein). GSK3␤ activity was measured by incubating immunoprecipitated GSK3␤ or, where indicated, recombinant GSK3␤ (New England Biolabs), in 30 l of kinase buffer [20 mM Tris, pH 7.5͞5 mM MgCl 2 ͞1 mM DTT͞250 M ATP͞1.4 Ci (1 Ci ϭ 37 GBq) of [␥-32 P]ATP, Amersham Pharmacia], with 0.1 g͞l recombinant tau protein (Panvera, Madison, WI) for 30 min at 30°C, and 25 l of Laemmli sample buffer (2% SDS) was added to stop the reaction. Samples were placed in a boiling water bath for 5 min, proteins were separated in 8% SDS polyacrylamide gels, and gels were vacuum-dried, exposed to a phosphoscreen overnight, and quantitated by using a PhosphorImager (Molecular Dynamics). The efficiency of GSK3␤ immunoprecipitation was determined by immunoblotting for GSK3␤. In indicated experiments, the activity of recombinant GSK3␤ was measured by using a primed substrate, phosphoglycogen synthase peptide-2 (Upstate Biotechnology), as described (11) except that the peptide concentration used was 25 M and the reaction time was 10 min.
Results
To study responses to DNA damage we used camptothecin, a topoisomerase I inhibitor that is well known to cause DNA damage, which subsequently activates p53-mediated responses. Camptothecin treatment of human neuroblastoma SH-SY5Y cells caused time-dependent (Fig. 1A ) and concentrationdependent (Fig. 1B) increases in the levels of p53 and p53-regulated protein p21 WAF1͞CIP1 . Subsequent to p53 accumulation there was increased proteolysis of the caspase-3 substrate PARP and increased activity of caspase-3, which is consistent with previous reports that DNA damage leads to p53-induced activation of the caspase-3-mediated apoptosis signaling cascade (4) (5) (6) .
To test whether GSK3␤ was influenced by DNA damage caused by camptothecin treatment, GSK3␤ was immunoprecipitated from camptothecin-treated cells, and its activity was assessed by measuring the phosphorylation of recombinant tau, a well characterized substrate of GSK3␤ (15) . These measure-ments revealed that camptothecin treatment resulted in a large and prolonged increase in the activity of GSK3␤ (Fig. 1C) . Because GSK3␤ is located in both the cytosolic and nuclear compartments of cells, and some apoptotic stimuli increase nuclear levels of GSK3␤ (13), these compartments were fractionated from control and camptothecin-treated cells to examine which pool of GSK3␤ was activated after DNA damage. Surprisingly, there was no nuclear translocation of GSK3␤ after camptothecin treatment, because both the nuclear and cytosolic levels of GSK3␤ remained unchanged, but there was an exclusive activation of nuclear, not cytosolic, GSK3␤ (Fig. 1D ). Nuclear GSK3␤ was activated within 1 h of camptothecin treatment and remained highly activated for at least 5 h (Fig. 1D) . Treatment with another agent that causes DNA damage, etoposide, also increased p53 levels and activated GSK3␤ in the nucleus (Fig.  1E ). These findings reveal a previously unrecognized effect of DNA damage, activation of GSK3␤ in the nucleus.
We examined the mechanisms underlying DNA damageinduced activation of GSK3␤, first focusing on potential changes in the phosphorylation state of GSK3␤. GSK3␤ is inhibited by phosphorylation of Ser-9 and activated by phosphorylation of Tyr-216 (7, 8, 16, 17) . However, after camptothecin treatment there were no changes in the levels of nuclear phospho-Ser-9-GSK3␤ ( Fig. 2A) or phosphotyrosine-GSK3␤ (data not shown). GSK3␤ activity also can be regulated by association with other proteins (7, 8) . For example, axin facilitates GSK3␤-mediated phosphorylation of ␤-catenin, and the inhibitory GBP inhibits GSK3␤ activity (18) (19) (20) . Therefore, we tested whether there might be a direct, regulatory association of GSK3␤ with p53 that accumulated in the nucleus after DNA damage by using coimmunoprecipitation measurements. Immunoblots revealed that p53 coimmunoprecipitated with GSK3␤ from nuclear fractions prepared from cells treated with camptothecin (Fig. 2B) . Similarly, camptothecin treatment resulted in the coimmunoprecipi- Fig. 1 . Camptothecin treatment activates p53, caspase-3, and GSK3␤. Cells in serum-free medium (2 h) were treated with 1 M camptothecin for 1-5 h (A) or 0, 0.3, 1, or 3 M camptothecin for 3 h (B). p53 and p21 levels and cleavage of intact PARP (116 kDa) to a stable breakdown product (85 kDa) were measured by immunoblot analysis, and caspase-3 activity (means Ϯ SEM; n ϭ 3) was measured by cleavage of a fluorogenic substrate, Ac-DEVD-AMC, as described (11) . (C) GSK3␤ activity was measured by immunoprecipitating GSK3␤ from cells treated with 1 M camptothecin for 0, 2, 3, 4 or 5 h and measuring the phosphorylation of recombinant tau by using [ 32 P]ATP as described (13) . (D) Cytosolic and nuclear fractions were prepared as described (13), followed by immunoprecipitation of GSK3␤ (IP'd GSK3␤). Treatment with 1 M camptothecin (CT) for 3 h did not alter the levels of GSK3␤ in either compartment but increased the activity of GSK3␤ in the nucleus but not the cytosol. Nuclear GSK3␤ activity was time-dependently increased from 1 to 5 h after treatment with 1 M camptothecin. (E) After treatment with 30 M etoposide (4 h) GSK3␤ was immunoprecipitated from nuclear fractions, and immunoprecipitants were used to immunoblot levels of p53 and GSK3␤ and measure the activity of GSK3␤.
tation of GSK3␤ with p53 (data not shown). Thus, DNA damage increased nuclear p53 levels and activated nuclear GSK3␤, and p53 formed a stable complex with GSK3␤ in the nucleus.
We tested whether p53, rather than other signals generated by DNA damage, accounted for activation of GSK3␤. p53 transiently transfected into p53-null H1299 lung carcinoma cells (14) Fig. 3 . Inhibition of GSK3␤ attenuates p53-mediated increases in p21 levels and PARP proteolysis. Preincubation for 1 h with inhibitors of GSK3␤, 20 mM lithium or 5 mM sodium valproate (VPA), attenuated 1 M camptothecininduced increases in p21 levels and PARP proteolysis (A) and attenuated these responses to treatment with 10 M etoposide (B). (C) PARP proteolysis induced by treatment with 1 M camptothecin (CT) was attenuated in cells stably expressing a dominant negative mutant of GSK3␤ (dn-GSK3␤), whereas increases in p53 levels were the same as in control cells. (D) Expression of nuclear GBP did not alter camptothecin-induced increases in p53 but reduced p21 levels and PARP proteolysis, reduced PARP proteolysis after treatment with 30 M etoposide (Etop), and reduced PARP proteolysis induced by treatment with either 1 or 5 M camptothecin. NLS, nuclear localization signal. (E) ␤-Catenin levels were reduced by camptothecin-induced activation of GSK3␤. ␤-Catenin was immunoblotted in nuclear, cytosolic, and membrane fractions prepared after treatment with 20 mM lithium (Li) for 4 h, 1 M camptothecin for 3 h, or both agents (LiϩCT).
Fig. 2. p53 associates with and activates GSK3␤. (A)
The phosphorylation state of nuclear and cytosolic GSK3␤ was measured after treatment with 1 M camptothecin for 0 -4 h. Phospho-Ser-9-GSK3␤ immunoreactivity was unaltered by camptothecin treatment. (B) p53 coimmunoprecipitated with nuclear GSK3␤. Cells were treated with 1 M camptothecin for 0 -5 h, nuclear fractions were prepared, GSK3␤ was immunoprecipitated, and the immunoprecipitates were immunoblotted for GSK3␤ and p53, which increased time-dependently in the GSK3␤-immunoprecipitates after camptothecin treatment. (C) Transient expression of wild-type (w-t) p53 but not mutant p53 (R175H) in p53-null H1299 lung carcinoma cells (O) increased the activity of nuclear GSK3␤. p53 or p53 (R175H) was transiently expressed, and after 24 h, nuclear fractions were prepared. GSK3␤ was immunoprecipitated from the nuclear fraction, GSK3␤ activity was measured, and immunoprecipitates were immunoblotted for GSK3␤ and p53. (D) p53 activates GSK3␤. The activity of recombinant GSK3␤ was measured in the presence of 0 -30 ng of recombinant p53, and the time-dependent phosphorylation of recombinant tau by recombinant GSK3␤ was measured in the absence (Ϫ) and presence (ϩ) of 50 ng of recombinant p53.
coimmunoprecipitated with GSK3␤, and expression of p53 was sufficient to increase the activity of nuclear GSK3␤ (Fig. 2C) . In contrast, mutant p53 (R175H), known to be functionally impaired, associated with but did not activate GSK3␤. This result indicated that the DNA damage-induced activation of GSK3␤ resulted from a regulatory association with p53. The association of p53 with GSK3␤, taken in conjunction with the lack of changes in GSK3␤ phosphorylation, raised the possibility that p53 may cause the activation of GSK3␤ directly. To test this hypothesis, the activity of recombinant GSK3␤ was measured in vitro in the absence and presence of recombinant p53. Remarkably, these measurements demonstrated that p53 directly increased the activity of recombinant GSK3␤, because GSK3␤ activity increased in a p53 concentration-dependent manner (Fig. 2D) . Because GSK3␤ phosphorylates substrates that are either unprimed, such as tau, or primed by previous phosphorylation (7, 8) , we examined recombinant GSK3␤-mediated phosphorylation of a primed substrate, phosphoglycogen synthase peptide-2, which also exhibited activation by recombinant p53 (n ϭ 3; P Ͻ 0.05 compared with GSK3␤ activity in the absence of p53; data not shown). Thus, these experiments have shown that p53 is capable of directly binding to GSK3␤, and this direct association increases the activity of GSK3␤.
In the Wnt pathway, scaffolding regulatory proteins control the specificity of GSK3␤-mediated signaling (7, 8) . Therefore, we reasoned that association with p53 might direct the actions of GSK3␤ to processes involved in p53-induced signaling. To examine this hypothesis, several methods were used to inhibit GSK3␤ activity to test whether this modulated p53 mediated responses after DNA damage. Pretreatment with lithium, a selective inhibitor of GSK3␤ (21-24), or a structurally dissimilar inhibitor of GSK3␤, sodium valproate (25) , reduced the camptothecin-induced increases in p21, PARP proteolysis (Fig. 3A) , and caspase-3 activity (data not shown). Lithium and sodium valproate pretreatment also attenuated etoposide-induced increases in p21 levels and PARP proteolysis (Fig. 3B) , and stable expression of a dominant negative mutant of GSK3␤ (26) also attenuated camptothecin-induced PARP proteolysis (Fig. 3C) . Thus, three treatments that reduce the activity of GSK3␤ attenuated signaling responses to p53. However, these conditions all reduce GSK3␤ activity throughout the cell. Therefore, we devised a method to selectively inhibit nuclear GSK3␤, the pool that is activated by p53. For this purpose, the inhibitory GBP (19, 26) was stably expressed by using a vector with a nuclear localization sequence. Immunoblots confirmed the exclusive nuclear localization of expressed GBP (data not shown). Expression of nuclear GBP did not alter camptothecin-induced increases in p53, but effectively attenuated elevations in the level of p21, and PARP proteolysis induced by camptothecin or etoposide even when a higher concentration (5 M) of camptothecin was tested (Fig. 3D) , confirming that nuclear GSK3␤ promotes DNA damage-induced, p53-mediated responses. Thus, not only is nuclear GSK3␤ activated by association with p53 after treatment with DNA-damaging agents, but activated nuclear GSK3␤ contributes substantially to the signaling activities induced by p53.
To test whether p53-activated nuclear GSK3␤ affected its interactions with other substrates, the levels of ␤-catenin were measured because active GSK3␤ promotes the degradation of ␤-catenin (7, 8) . Treatment with camptothecin reduced cytosolic ␤-catenin but not membrane-bound ␤-catenin, which is sequestered from accessibility by GSK3␤, and this effect was blocked by inhibition of GSK3␤ with lithium (Fig. 3E) .
Discussion
This identification of a direct, activating interaction between p53 and GSK3␤ reveals new mechanisms that regulate the actions of each of these proteins, provides a mechanistic explanation for several previously reported findings, and raises potentially new therapeutic strategies. Although several studies have reported that GSK3␤ is involved in apoptotic signaling, in most cases it was inferred from overexpression or inhibition of GSK3␤. When endogenous GSK3␤ was found to be activated during apoptosis, the mechanism was attributed to changes in the phosphorylation state of GSK3␤ (7) (8) (9) (10) (11) (12) . The observed activation of GSK3␤ in response to DNA damage, which previously was not known to activate GSK3␤, is unique because the phosphorylation state of GSK3␤ was unaltered and only nuclear GSK3␤ was activated, although the majority of cellular GSK3␤ is in the cytosol (13) . It is now evident that these unique features are caused by the mechanism found to activate GSK3␤ after DNA damage, the association with p53, and the predominantly nuclear localization of p53. It is intriguing to note that this interaction provides a mechanism for p53 to down-regulate several survival-promoting transcription factors that are known to be phosphorylated by GSK3␤ in the nucleus (reviewed in ref. 8) , the inhibition of which would promote p53's activation of the apoptotic program. Previously GSK3␤ was known to be regulated by protein complex formation, because axin and axin-related proteins can facilitate the phosphorylation of ␤-catenin by GSK3␤ (7, 8, 18, 20) , and other GSK3␤-binding proteins such as GBP can inhibit this process (7, 8, 15, 19, 20) . However, the regulation of GSK3␤ by protein complexes was known only to occur in the context of the Wnt͞wingless signaling pathway. Thus, activation of GSK3␤ by binding to p53 reveals that protein complexes outside the Wnt͞wingless pathway also regulate the activity of GSK3␤, which raises the possibility that additional proteins bind and regulate GSK3␤ independently of Wnt͞wingless signaling. This interaction likely accounts for the findings that (i) expression of dominant negative p53 blocked apoptosis induced by overexpression of GSK3␤ (10), (ii) activation of Akt (protein kinase B), which inhibits GSK3␤, is inhibitory for p53-mediated transcriptional and apoptotic activities (27) (28) (29) , and (iii) activated p53 down-regulates ␤-catenin (30), because GSK3␤ promotes proteolysis of ␤-catenin (7). Furthermore, the broad cell survivalpromoting effects of the GSK3␤ inhibitor lithium (8, 31, 32) may be attributable partly to attenuated p53 function (32, 33) consequential to GSK3␤ inhibition such as in ischemic brain, where lithium is protective (31) . The revelation that GSK3␤ modulates p53 function presents opportunities for regulating the effects of p53. For example, chemotherapeutic p53-mediated signaling could be enhanced by activating GSK3␤, and p53-mediated neuronal loss may be attenuated by inhibitors of GSK3␤, although potential proliferative͞cancerous effects must be assessed. Thus, these findings reveal mechanisms involved in DNA damage-induced intracellular signaling and raise possibilities for pharmacologically modulating cellular responses to DNA damage.
